475 assets in Plasma Cell Myeloma

Therapeutic assets addressing Plasma Cell Myeloma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pegenzileukin Plasma Cell Myeloma	Sanofi	P1/2	CCC (48)
phe885 Plasma Cell Myeloma	Novartis Pharmaceuticals	P2	CCC (48)
Purinostat Plasma Cell Myeloma	Chengdu Zenitar Biomedical Technology Co., Ltd	P1/2	CCC (48)
Regn17372 Plasma Cell Myeloma	Regeneron Pharmaceuticals	P1/2	CCC (48)
Anti-Tgf-Beta Monoclonal Antibody Sar-439459 Plasma Cell Myeloma	Sanofi	P1/2	CC (47)
Autologous Bcma/Cd19 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Bcma/Cd38 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Bcma/Gprc5D Dual-Target Car-T Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd19/Cd20 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd19/Cd22 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd33/Cd123 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd33/Cll1 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd5/Cd7 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Melphalan Flufenamide Plasma Cell Myeloma	Fondazione EMN Italy Onlus	P3	CC (47)
Anti-Bcma-Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CC (46)
Auto Car T Cell Therapy Plasma Cell Myeloma	Autolus Limited	P2	CC (46)
Axitinib Plasma Cell Myeloma	Canadian Cancer Trials Group	P2	CC (46)
AXUMIN Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (46)
Bms-986345 Plasma Cell Myeloma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (46)
Capivasertib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (46)
Cellprotect Plasma Cell Myeloma	Karolinska Institutet	P2	CC (46)
Copanlisib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CC (46)
Defactinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (46)
Degarelix Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (46)
Duvelisib Plasma Cell Myeloma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (46)
Elranatamab-Bcmm Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (46)
Emapalumab Plasma Cell Myeloma	NYU Langone Health	P2	CC (46)
Fam-Trastuzumab Deruxtecan-Nxki Plasma Cell Myeloma	American Society of Clinical Oncology	P2	CC (46)
Human Hyaluronidase Isozyme-5 (Hyal5, Sperm Adhesion Molecule 1, Spam1, Hyaluronidase Ph-20, Ec:3.2.1.35) Fragment (3-433, 1-431 In The Current Sequence) Engineered Variant With The Structural Domain Replaced By The Corresponding Region Of Human Hyaluronidase Isozyme-1 (Hyal1)(<Sup>306</Sup>Tlsimrsmkscllddnymeti<Sup>326</Sup>><Sup>304</Sup>Swentrtkescqaikeymdtt<Sup>324</Sup>), Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Dg44, Glycoform Alfa Plasma Cell Myeloma	Barbara Ann Karmanos Cancer Institute	P2	CC (46)
Igpro20 Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (46)
Ipatasertib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (46)
Larotrectinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (46)
Leuporelin Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (46)
Mecapegfilgrastim Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CC (46)
Mit-001 Plasma Cell Myeloma	MitoImmune Therapeutics	P2	CC (46)
Osimertinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (46)
pd-1ab21-bcma car-t cell immunotherapy Plasma Cell Myeloma	Daihong Liu	P2	CC (46)
Plinabulin Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (46)
Talazoparib Plasma Cell Myeloma	American Society of Clinical Oncology	P2	CC (46)
Tcr Transduced T-Cells Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (46)
Tucatinib Plasma Cell Myeloma	Canadian Cancer Trials Group	P2	CC (46)
Ulixertinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (46)
Universal Donor Expanded Tgf-Beta-Imprinted Nk Cells Plasma Cell Myeloma	Elvira Umyarova	P1	CC (46)
Abbv-453 Plasma Cell Myeloma	AbbVie	P1/2	CC (45)
Adavosertib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (45)
Bosutinib Plasma Cell Myeloma	Canadian Cancer Trials Group	P2	CC (45)
bt02 Plasma Cell Myeloma	Biotroy Therapeutics	P1/2	CC (45)
Fully Human Bcma Chimeric Antigen Receptor Autologous T Cell Plasma Cell Myeloma	Nanjing IASO Biotechnology Co., Ltd.	P1/2	CC (45)
Gic-102 Plasma Cell Myeloma	GI Cell, Inc.	P1/2	CC (45)
Hdp-101 Plasma Cell Myeloma	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P1/2	CC (45)

Showing 201 to 250 of 475 assets

PreviousPage 5 of 10Next